Who is the CEO of Kallyope? Nancy Thornberry's Bio

Date
September 27, 2024

Nancy Thornberry is the CEO of Kallyope, a biotechnology company focused on gut-brain axis therapeutics. With a background in biochemistry and a notable career at Merck, she has led Kallyope in pioneering research and development efforts. Under her leadership, the company has made significant strides in understanding gut biology and advancing novel therapeutic programs.

Who is the CEO of Kallyope?

Nancy Thornberry – CSHL WiSE

With a distinguished career in biochemistry, Nancy Thornberry has made significant contributions to the biotechnology and pharmaceutical industries. She began her journey at Merck Research Laboratories, where she held various leadership roles, including Senior Vice President and Franchise Head of Diabetes and Endocrinology. Thornberry's expertise in metabolic disorders and drug discovery led to the development of groundbreaking treatments for Type 2 diabetes. In 2015, she became the founding CEO of Kallyope, a company dedicated to exploring the gut-brain axis for therapeutic advancements.

Her leadership has been instrumental in positioning Kallyope at the forefront of gut biology research, driving innovative programs that aim to improve health and nutrition.

Work History

Nancy Thornberry's extensive work history showcases her vast experience and leadership in the biotechnology and pharmaceutical industries. Here is a detailed list of her previous roles:

  • Vertex Pharmaceuticals: Member, Board of Directors: December 2023 - Present
  • Adimab: Member, Board of Directors: December 2023 - Present
  • New York Genome Center: Member, Board of Directors: October 2022 - Present
  • GV: Advisor: July 2022 - Present
  • Kallyope: Member, Board of Directors and Chair, R&D: October 2021 - Present
  • Kallyope: CEO: November 2015 - September 2021
  • Schrödinger: Member, Board of Directors: October 2019 - Present
  • Denali Therapeutics: Member of the Board of Directors: January 2021 - Present
  • Merck Research Labs: Senior Vice President and Franchise Head, Diabetes and Endocrinology: April 2011 - July 2013
  • Merck & Co., Inc.: Senior Vice President and Franchise Head, Diabetes and Obesity: September 2009 - April 2011
  • Merck Research Labs: Vice President, Worldwide Basic Research Head, Diabetes and Obesity: February 2007 - September 2009
  • Merck Research Labs: Executive Director, Metabolic Disorders: January 2004 - February 2007
  • Merck Research Labs: Senior Director, Metabolic Disorders: January 2002 - January 2004
  • Merck Research Labs: Director, Metabolic Disorders: January 2001 - January 2002
  • Merck Research Labs: Director, Enzymology: January 1999 - January 2001
  • Merck Research Labs: Senior Research Fellow, Enzymology: January 1997 - January 1999
  • Merck Research Labs: Research Fellow, Enzymology: January 1993 - January 1997
  • Merck Research Labs: Senior Research Biochemist, Enzymology: January 1989 - January 1993
  • Merck Research Labs: Research Biochemist, Enzymology: January 1986 - January 1989
  • Merck Research Labs: Staff Biochemist, Enzymology: January 1983 - January 1986
  • Merck Research Labs: Biochemist, Enzymology: January 1979 - January 1982
  • Education History

    Nancy Thornberry's educational journey began at Muhlenberg College, where she pursued a Bachelor of Science degree in Chemistry and Biology. From 1975 to 1979, she immersed herself in the study of these scientific disciplines, laying a strong foundation for her future career in biochemistry and biotechnology. Her time at Muhlenberg College was marked by a rigorous academic curriculum that equipped her with the knowledge and skills necessary to excel in the pharmaceutical and biotechnology industries.

    When did Nancy Thornberry join Kallyope?

    In 2015, Nancy Thornberry became the founding CEO of Kallyope, a biotechnology company dedicated to exploring the gut-brain axis for therapeutic advancements. She held the CEO position until September 2021, after which she transitioned to the role of Chair of Research and Development while continuing to serve on the Board of Directors. This means she has been with Kallyope for nearly eight years, contributing significantly to its growth and pioneering research efforts.

    Share Article

    More Articles

    Start molding your dream campaigns today

    Start your 14-day Pro trial today. No credit card required.